The anti‐CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6‐month, open‐label Phase I clinical trial
Rodríguez, P. C., Prada, D. M., Moreno, E., Aira, L. E., Molinero, C., López, A. M., Gómez, J. A., Hernández, I. M., Martínez, J. P., Reyes, Y., Milera, J. M., Hernández, M. V., Torres, R., Avila, Y., Barrese, Y., Viada, C., Montero, E., Hernández, P.
Published in Clinical and experimental immunology (01.02.2018)
Published in Clinical and experimental immunology (01.02.2018)
Get full text
Journal Article